Fabienne Quentin

  • Citations Per Year
Learn More
BACKGROUND Generation of additional evidence may be necessary to access new promising technologies (marketing approval or coverage). Access with evidence generation (AEG) is a more recent concept with regard to coverage than to marketing approval. OBJECTIVES One aim of Work Package 7 (WP7) Strand A of the European network for Health Technology Assessment(More)
BACKGROUND Several countries have developed policy frameworks allowing timely access to promising health technologies on the condition that additional evidence is generated. However, an important barrier to evidence generation is the lack of structured collaboration among health technology assessment (HTA) agencies. OBJECTIVES One of the aims of Work(More)
  • 1